| ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment? C Hobeika, G Rached, R Eid, F Haddad, S Chucri, HR Kourie, J Kattan Personalized medicine 15 (2), 111-115, 2018 | 26 | 2018 |
| Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11 L Zhang, CS Hobeika, D Khabibullin, D Yu, H Filippakis, M Alchoueiry, ... Proceedings of the National Academy of Sciences 119 (28), e2122840119, 2022 | 25 | 2022 |
| Urging medical students to publish: Advantages, disadvantages and new challenges G Rached, C Hobeika, E Karam, HR Kourié, J Kattan Bulletin du Cancer 105 (6), 626-628, 2018 | 4 | 2018 |
| 116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis T El Zarif, G Pond, A Nassar, E Adib, D Freeman, J Thomas, U Kalluri, ... Annals of Oncology 33, S591-S592, 2022 | 1 | 2022 |
| Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms. C Labaki, L Zhang, Y Hou, K Bi, C Hobeika, Z Bakouny, SY Camp, ... Journal of Clinical Oncology 40 (16_suppl), 4549-4549, 2022 | 1 | 2022 |
| Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target C Hobeika, G Rached, A Chebly, E Chouery, HR Kourie Pharmacogenomics 21 (13), 957-962, 2020 | 1 | 2020 |
| Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH). DR Bakaloudi, D Makrakis, R Talukder, LN Diamantopoulos, T Jindal, ... Journal of Clinical Oncology 42 (16_suppl), 4580-4580, 2024 | | 2024 |
| Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic … C Hobeika, S Dawsey, U Patgunarajah, D Lynn, N Pramod, W Wei, M Nair, ... Journal of Clinical Oncology 42 (16_suppl), 4589-4589, 2024 | | 2024 |
| Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions C Hobeika, F Bicer, K Abouelezz, S Gupta Advances in Oncology 4 (1), 199-206, 2024 | | 2024 |
| Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world … D Lynn, S Dawsey, U Patgunarajah, N Pramod, W Wei, C Hobeika, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 678-678, 2024 | | 2024 |
| Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting. D Lynn, C Hobeika, U Patgunarajah, S Dawsey, N Pramod, W Wei, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 571-571, 2024 | | 2024 |
| Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC). N Pramod, S Dawsey, U Patgunarajah, D Lynn, W Wei, C Hobeika, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 703-703, 2024 | | 2024 |
| Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting. C Hobeika, S Dawsey, U Patgunarajah, D Lynn, N Pramod, W Wei, M Nair, ... Journal of Clinical Oncology 42 (4_suppl), 640-640, 2024 | | 2024 |
| Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). C Labaki, M Alchoueiry, K Bi, L Zhang, C Hobeika, Z Bakouny, ... Journal of Clinical Oncology 42 (4_suppl), 476-476, 2024 | | 2024 |
| Papillary Renal Cell Carcinoma: Current Evidence and Future Directions A Jang, CS Hobeika, S Gupta Kidney Cancer 8 (1), 61-79, 2024 | | 2024 |
| Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms C Labaki, M Al-Choueiry, J Nyman, Y Hou, K Bi, L Zhang, C Hobeika, ... The Oncologist 28 (Supplement_1), S7-S8, 2023 | | 2023 |
| Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment M Alchoueiry, C Labaki, L Zhang, Y Hou, K Bi, C Hobeika, JC Wells, ... Cancer Research 83 (16_Supplement), B019-B019, 2023 | | 2023 |
| Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms. C Labaki, C Hobeika, Y Hou, L Zhang, K Bi, Z Bakouny, SY Camp, ... Journal of Clinical Oncology 41 (16_suppl), 4558-4558, 2023 | | 2023 |
| 9.3 The Psychiatric Comorbidities of Sickle Cell Disease in Youth G Rached, C Hobeika, D Fiani, SM Dib, E Saad, S Torbey Journal of the American Academy of Child & Adolescent Psychiatry 60 (10), S174, 2021 | | 2021 |
